Clinical Cases in Advanced Prostate Cancer | Expert Perspective Tumor Board

Experts in genitourinary cancer review 2 clinical cases and address major changes in the management of patients with castration-resistant prostate cancer.

EP 1: Case 1: MRI/TRUS Fusion Biopsy for Nonmetastatic CRPC

Jorge A. Garcia, MD, FACP, describes the case of a 57-year-old African American man with nonmetastatic castration-resistant prostate cancer, and Ganesh V Raj, MD, PhD, reviews how the MRI/TRUS fusion biopsy is becoming a mainstay in diagnosis.

EP 2: Case 1: Novel Imaging Used for Nonmetastatic CRPC

Experts in genitourinary oncology share their use of novel imaging in practice for nonmetastatic castration-resistant prostate cancer.

EP 3: Case 1: Approach to Radiation for Nonmetastatic CRPC

Ganesh V Raj, MD, PhD, shares his approach to radiation therapy in patients with nonmetastatic castration-resistant prostate cancer.

EP 4: Case 1: Initiating ADT for Nonmetastatic CRPC

Mary-Ellen Taplin, MD, reviews the criteria used to initiate androgen deprivation therapy in the setting of rising PSA syndrome for patients with nonmetastatic castration-resistant prostate cancer.

EP 5: Case 1: Role of Genetic Testing in Nonmetastatic CRPC

Ganesh V Raj, MD, PhD, and Mary-Ellen Taplin, MD, review the role of next-generation sequencing in nonmetastatic castration-resistant prostate cancer, and who qualifies based on NCCN guidelines.

EP 6: Case 1: Therapy Selection for Nonmetastatic CRPC

Experts in genitourinary oncology share their methods and patient specific factors that aid in selecting therapy for nonmetastatic castration-resistant prostate cancer.

EP 7: Case 1: Antiandrogen Therapy for Nonmetastatic CRPC

Experts in genitourinary oncology share how they decide between the 3 antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: apalutamide, enzalutamide, and darolutamide.

EP 8: Case 1: Therapy and Long PSA Doubling Time in nmCRPC

Experts in genitourinary oncology discuss how they choose therapy for patients with long PSA doubling times in nonmetastatic castration-resistant prostate cancer (nmCRPC).

EP 9: Case 1: SPARTAN Trial for Apalutamide in nmCRPC

Ganesh V Raj, MD, PhD, presents data from the phase 3 SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).

EP 10: Case 1: PROSPER and ARAMIS Trials for nmCRPC

Patrick G. Pilié, MD, presents data from the phase 3 PROSPER trial of enzalutamide, and Ganesh V Raj, MD, PhD, presents data from the phase 3 ARAMIS trial of darolutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).